

REDX PHARMA PLC
("Redx" or "the Company" or "Redx Pharma")

Redx Pharma to present at the Cowen 41st Annual Health Care Conference

Alderley Park, 25 February 2021 Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, today announces that Lisa Anson, Chief Executive Officer, will give an update on progress made by the Company, at the Cowen 41st Annual Health Care Conference on Thursday 4 March, 2021 at 16:10 GMT / 11:10 EST.

A live webcast of the presentation will be available for viewing at:

<https://wsw.com/webcast/cowen81/redx.l/2192577>

Following the event, a recording will be made available on the investor section of the Company's website at: <https://www.redxpharma.com/investor-centre/presentations-analyst-reports-documents-and-videos/>.

For further information, please contact:

Redx Pharma Plc

Iain Ross, Chairman
Lisa Anson, Chief Executive Officer
James Mead, Chief Financial Officer

T: +44 1625 469 918

SPARK Advisory Partners (Nominated Adviser)

Matt Davis/Adam Dawes

T: +44 203 368 3550

WG Partners LLP (Broker)

Claes Spång/Chris Lee/David Wilson

T: +44 20 3705 9330

FTI Consulting

Simon Conway/Ciara Martin

T: +44 20 3727 1000

About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical Proof of Concept. Redx's lead oncology asset, RXC004, is currently in a Phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a Phase 1 clinical study in H1 2021.

The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).